In the pharmaceutical industry, waste represents at least 25% of the cost of quality. In 2004, the Food and Drug Administration (FDA) published a guide to promote the implementation of Process Analytical Technologies (PATs) in the pharmaceutical industry. This would allow better quality control (QC) and monitoring directly on the production line.
The FDA has encouraged manufacturers to use the PAT framework to develop and implement effective and efficient innovative approaches in pharmaceutical development, manufacturing and quality assurance, including continuous real-time quality assurance.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Can’t attend live? No worries – register to receive the recording post-event.
Typically, a limited number of tablets are randomly sampled within a batch for routine analysis. For a batch of a few million tablets, usually only between 10 and 30 are tested.2 The batch is then put in quarantine until QC results are obtained, which generates storage costs and reduces the company’s flexibility to respond to customer’s requirements. If the number of detected faulty tablets is higher than the Acceptance Quality Level, the batch will be manually sorted, reworked, or completely rejected and remanufactured – all of which lead to significant temporal and financial losses.
This article presents an automatic sorting system capable of testing every tablet, without creating a bottleneck for the production line.
Several QC parameters can be alternatively analysed by PATs, such as Near-Infrared Spectroscopy (NIRS) using multivariate models. Initial NIRS applications were performed off-line using a few tablets for testing.3 Offline analyses showed good correlations between studied tablet concentrations and NIR predictions, but this methodology could not be used for in-process tablet monitoring during the manufacturing process, due to lack of time and resources.
Figure 1: VisioNIR equipment scanning tablets
More recently, the development of in-line rapid technologies has facilitated the possibility of using NIRS to monitor the manufacturing process. In-line tablet monitoring has been discussed in several articles. Tablet chemical composition has been tested via NIRS immediately after compression4 at much lower speeds (6,000 tablets/hour) than those encountered during commercial production (60,000-170,000 tablets/hour).
This study presents work on the NIR acquisition of each tablet coming off a tablet press, achieving high-speed sample presentation to the probe in a consistent manner. A portion of the data was used to calibrate a model able to predict the composition of each tablet. We added a NIR probe to a vision-based system, enabling chemical composition as a sorting criterion. This system was used to discard the tablets with over- or under-potency defects.
Materials and methods
Equipment
The Teonys tablet sorting equipment (Proditec, France) was used to carry out the spectral acquisition. The commercial version is equipped with a colour line-scan camera capable of sorting tablets according to their visual appearance (ie, identifying shape and defects). Even if the machine can reach speeds of up to 300,000 tablets per hour with 5mm round tablets, when both conveyor belts are working simultaneously, this study was led at 55% of its capacity due to tablet shape and roughness.
In this research, a VisioNIR LS probe (Visiotec, Germany), working in reflectance mode, was installed on the commercial Teonys system. Located downstream of the camera, the spectral acquisitions were triggered when a tablet was detected by the visible imaging system. Each tablet was scanned once (single NIR scan) using an integration time of 0.5 milliseconds.
Tablets
The tablet ingredients used for the tests consisted of different concentrations of Ibuprofen. Five blends (A-E) with different concentrations of Ibuprofen pellets were prepared. The concentrations of excipients 1 – 4 were varied to compensate for the changes in Ibuprofen concentration (Table 1). Excipient 5 was kept constant at 1% w/w.
During compression, the blends were sequentially added in a random order (2, 8, 18, 0 and 15.8% w/w) with no interruption between the batches, thus creating transition tablets. Tablet compression was performed at a rate of 23,000 tablets / hour. Tablets were collected at intervals of one minute during the steady-state phases, and at intervals of 15 seconds for 4.5 minutes during the transition phases. A total of 51,458 tablets were thus collected. All the transition-phase and stable-phase tablets were scanned using the VisioNIR probe (850-1650nm – 3nm resolution). The probe was run at an integration time of 0.5ms per spectrum.
312 of these tablets were sub-sampled to calibrate the model. A UV-assay at 264nm was used as a reference method to quantify true Ibuprofen concentrations in the tablets (Table 2). Results show that the five blends approach the expected Ibuprofen concentrations but differ somewhat, possibly due to experimental errors or powder segregation. These assay values, rather than the expected concentrations, were used to calibrate the NIR probe.
Chemometrics
The calibration set (Xcal (312×256)) was composed of NIR spectra of sub-samples acquired by the VisioNIR system, and the Ibuprofen content responses ycal (312×1) found by the assay. The validation matrix Xval (51,458×256) was composed of NIR spectra of all the tablets acquired by the VisioNIR system. Using the Unscrambler X 10.4 software, a 2-component Partial Least Squares (PLS) model was built between Xcal and ycal. Spectra were first cropped between 1051-1201nm and pretreated using SNV and a 2nd derivative Savitzky-Golay. Raw and pretreated spectra are shown in Figure 2. A characteristic absorption peak for Ibuprofen around 1,130nm7 is clearly present in Figures 2b and 2c.
Figure 2: Spectra of the tablets: (a) raw spectra, (b) after SNV and Savitsky-Golay 2nd derivative, and (c) ibuprofen peak around 1130 nm.
The following results are quantified in terms of their R2 and RMSE values. R2 is defined as the strength of a linear relationship between two random variables. It ranges between [0-1] – higher values indicate a better model. Root mean square error (RMSE) measures the difference between predicted and measured response values. Expressed in the same unit as the original response values, it ranges between [0-∞] – lower values indicate a better model. These two indices were used to quantify model performance.
Results and discussion
A PLS model was used to predict the API content of the tablets. The Ibuprofen content of the 312 sub-sampled tablets used to calibrate the model were then predicted via cross-validation. We obtained a R2 equal to 0.93 for cross-validation and a RMSE CV of 1.85% w/w of Ibuprofen. These results mirror those obtained by the UV reference method (Table 2).
Following this, the concentration of all the tablets (51,458) were predicted. For experimental reasons, tablets were gathered in lots of 100 during transition periods (following the step changes) and in lots of 380 during steady state production periods. As temporal information was lost within each lot, we present the average NIR results for each lot in Figure 3. These results show the NIR predicted concentration in which four transitions are clearly shown in response to the concentration step changes applied to the system. Furthermore, these results show a good agreement between the NIR and UV assay results within the steady states: RMSEP of 2.09% w/w Ibuprofen. A small increase in concentration during the transition at 85 minutes matched the UV results, adding credence to the notion that NIR can be used to detect even small variations in tablet contents (possibly as low as 1% as illustrated in Figure 3).
Figure 3: Steady-state and transition Ibuprofen contents for lots of tablets.
While Figure 3 illustrated averaged Ibuprofen results, a prediction was made for each individual tablet. Table 3 presents the maximum and minimum concentrations predicted for individual tablets within each of the five steady states.
These results show significant tablet-to-tablet variations throughout the run. This variability may be attributed to several factors:
Tablet presentation. Variability in the presentation of the oblong tablets to the probe may be present (Figure 1). This is specific to the scanning system employed and may be addressed by optimising the operation parameters and system geometry (eg, shape of the feeder wheel).
NIR scanning. The NIR spectra are acquired in reflectance from a portion of the tablet. Any segregation in tablet composition will lead to a biased estimation of that tablet’s composition. This may be addressed with a larger spot size, working with multiple NIR probes located around the tablets, or by acquiring transmitted NIR light.
The tablet-to-tablet variability observed in the NIR results may simply be caused by the fact that the tablets actually present such a large individual variability. This appears to be supported by large variability also present in the UV assay results (Table 3). Such a fact clearly underlines the need for 100% tablet inspection.
Conclusion
This study is a proof of concept for using online NIR spectroscopy to monitor the Ibuprofen concentration changes in uncoated tablets. Content differences as low as 2% ibuprofen, as well as minor Ibuprofen quantity variations during transition, were successfully captured. However, RMSE of 1.85% and 2.09% for cross-validation and prediction indicate the limitations of this method. In the case of discriminating similar products, it is necessary to make a preliminary analysis to define the risk, depending on the type of active ingredient as well as its concentration in the blend.
An inspection of 100% of the batch is possible, avoiding time and money losses for the company. This type of analysis may eventually be added to the current visual, or cosmetic, inspections. In doing so, products with surface defects and/or out-of-specification API content may be identified and discarded.
Table 1: Tablet formulation
Blend
A
B
C
D
E
Ingredients
% w/w concentration
Ibuprofen
0.00
2.00
8.00
15.80
18.00
Excipient 1
82.37
80.40
75.66
69.12
67.40
Excipient 2
11.85
11.80
10.96
10.06
9.70
Excipient 3
2.39
2.40
2.19
2.01
1.95
Excipient 4
2.39
2.40
2.19
2.01
1.95
Excipient 5
1.00
1.00
1.00
1.00
1.00
Table 2: Assay results of the sub-sampled tablets. Values in parenthesis are standard deviations.
Ipubrofen concentration
(% w/w)
Blend
A
B
C
D
E
Expected
0
2
8
15.8
18
UV-assay
0.7 (0.9)
1.9 (0.1)
7.0 (0.7)
13.8 (1.3)
17.2 (1.5)
NIR
1.0 (1.3)
1.7 (0.7)
7.7 (1.5)
14.7 (1.6)
15.8 (1.6)
Table 3: Steady-state Ibuprofen content for individual tablets. Values in parenthesis are standard deviations.
Blend
UV assay
(% w/w)
NIR predicted Ibuprofen
(% w/w)
Minimum
Maximum
Average
A
0.7 (0.9)
-0.7
2.6
-0.2
B
1.9 (0.1)
0.2
2.9
2.0
C
7.0 (0.7)
4.5
9.3
8.0
D
13.8 (1.3)
11.5
17.5
13.2
E
17.2 (1.5)
12.6
18.5
15.9
References
Kieffer R. The impact of waste on the cost of quality in the pharmaceutical industry, PDA letter, February 8th 2016.
Uniformity of dosage units (2016), USP 905.
Blanco M, Coello J, Iturriage H, Maspoch N. (2001). Influence of the procedure used to prepare the calibration sample set on the performance of near infrared spectroscopy in quantitative pharmaceutical analyses. The Analyst 126, p.1129-1134.
Karande AD, Heng PW, Liew CV. (2010). In-line quantification of micronized drug and excipients in tablets by near infrared (NIR) spectroscopy: Real time monitoring of tabletting process. International Journal of Pharmaceutics. 396(1-2), p.63-74.
Romañach RJ, Hernández Torres E, Roman Ospino A, Pastrana Otero I, Semidei Ortiz FM. (2014). NIR and Raman Spectroscopic Experiments to Train the Next Generation of PAT Scientists. American Pharmaceutical Review. November 27.
Biographies
ALYSSA LANGLET is project leader for the development of a high-speed systematic tablet analysis tool for Pfizer and the University of Sherbrooke. With a masters’ in chemical engineering in Canada and two industrial engineering degrees in France and Spain, Ms. Langlet spent several years in both the railway and aerospace industries before joining the Pfizer Chair on process analytical technologies in pharmaceutical engineering.
HIMMAT DALVI received his PhD in chemical engineering from University of Sherbrooke, working with the Pfizer research chair in process analytical technologies. His research interests include pharmaceutical pre-formulation studies, formulation development, technology transfer and development of PAT tools for process understanding as well as continuous process monitoring. He has more than eight years of experience in pharmaceutical formulation research and development. He played a key role in the development of multiple drug formulations for new chemical entities as well as generic formulations and technology transfers at commercial scale.
JEAN-MAXIME GUAY is a Senior Scientist leading PAT development and implementation initiatives at Pfizer. He joined Pfizer’s Manufact`1uring Process Analytics and Control group (MPAC) in 2012. Jean-Maxime previously earned BA degrees in bioinformatics and biotechnological engineering. He is currently responsible for the technical support and implementation of Rapid Analytics in manufacturing sites within the Consumer Healthcare and Sterile Injectable operating units. He is also part of the Automated Quality Verification Technologies (AQVT) team involved in supporting PGS sites on automated inspection technology projects.
ANTOINE COURNOYER is Manager at Pfizer – PAT Projects within the MPAC (Manufacturing Process Analytic and Control) Team in GTS. In his role, he currently supports PAT and Process Analytics development and implementation projects for Consumer, Local Market and Sterile injectable sites, mainly across North America, Europe and Asia. Antoine joined Pfizer in 2003 working in Technical Services at the Montréal manufacturing site. He then became PAT Scientist and worked in a global PAT development and implementation role as part of the Montréal team. Antoine holds an MBA, a Master in Pharmaceutical sciences, and a Bachelor in Chemical Engineering.
RYAN GOSSELIN is an associate professor in the Department of Chemical Engineering and Biotechnological Engineering at University of Sherbrooke, Canada. He specialises in process engineering and on-line quality monitoring through the use of multivariate data analysis, chemometrics and data mining. His work mainly focuses on industrial process optimisation through the use of spectral and imaging probes. He co-chairs the Pfizer Industrial Research Chair on Process Analytical Technologies (PAT) in pharmaceutical engineering.
The rest of this content is restricted - login or subscribe free to access
Thank you for visiting our website. To access this content in full you'll need to login. It's completely free to subscribe, and in less than a minute you can continue reading. If you've already subscribed, great - just login.
Why subscribe? Join our growing community of thousands of industry professionals and gain access to:
bi-monthly issues in print and/or digital format
case studies, whitepapers, webinars and industry-leading content
breaking news and features
our extensive online archive of thousands of articles and years of past issues
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.